As previously reported at the annual meeting of the American Academy of Allergy, Asthma & Immunology and published in The Lancet in 2023, garadacimab reduced investigator-confirmed HAE attacks by ...

About Hereditary Hemorrhagic Telangiectasia (HHT) ‍HHT is a rare disease that affects more than 150,000 people in the U.S. and EU, and for which there are currently no approved therapies.

WATERTOWN, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling with clustering antibodies that address the underlying ...

The FDA on Tuesday signed off on CSL’s Factor XIIa blocker garadacimab to prevent attacks in patients with hereditary angioedema. The biologic will be marketed under the brand name Andembry.

FDA Delays Decision On KalVista's Sebetralstat NDA For Hereditary Angioedema June 13, 2025 — 11:55 pm EDT Written by RTTNews.com for RTTNews -> ...

Key teaching points highlighted in this case include hereditary hemorrhagic telangiectasia (HHT) sign/symptom recognition, standard-of-care diagnostic workup, and an introduction to iron ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will not meet the PDUFA goal date for the New Drug ...

Hereditary haemorrhagic telangiectasia (HHT) is diagnosed clinically by the Curaçao Criteria of spontaneous recurrent nosebleeds, mucocutaneous telangiectasia at characteristic sites, visceral ...

Anticoagulant-related hemorrhages are associated with increased hematoma volume and expansion, as well as increased morbidity and mortality. 84–86 Admission anemia is associated with hemorrhagic ...

For people diagnosed with macular telangiectasia type 2 (MacTel)-a rare and slowly progressing retinal disease-there have been no FDA-approved (or other) treatments to slow or stop vision loss.